Description
Pancragen (Lys-Glu-Asp-Trp) is a synthetic tetrapeptide of the Khavinson bioregulator class with tissue-specific action on the pancreas, particularly endocrine islet cell function. The substance was developed at the St. Petersburg Institute for investigating age-related pancreas function changes.
Per study reports Pancragen modulates gene expression in beta and alpha cells of the pancreas via the Khavinson epigenetic mechanism. Preclinical studies describe effects on insulin secretion kinetics, islet cell regeneration, and glucose metabolism markers in aging models.
In Russian research literature Pancragen is used in pre-diabetes and type-2 diabetes research setups, with documented improvements in fasting glucose and HbA1c in older populations.
Typical application is subcutaneous in 10-20 day courses two to three times per year.
You can order Pancragen as lyophilized peptide in 10-pack at 20mg per vial.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Pancragen is classified as very mild in the available literature and is among the most well tolerated compounds of the Khavinson bioregulator class. In the available preclinical and limited human studies, no relevant toxic effects have been documented.
Observed in research and reports:
- Injection site: mild redness or transient irritation with subcutaneous use is the most common observation. The tetrapeptide itself is considered low-reactivity.
- Very thin human data: the data base consists almost entirely of small, Russian-language studies from the Khavinson environment. Independent peer-reviewed replication and robust long-term data on use in glucose metabolism are absent.
- Course-based pattern: the use described occurs in short 10-20 day courses. No data exist on the safety profile of continuous administration.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Tetrapeptide stimulates functional activity of pancreatic cells in aging - Advances in Gerontology 2013, Khavinson, Sevostyanova and Durnova: KEDW increases proliferation and anti-apoptosis markers in aged pancreatic cell cultures.
- Peptide bioregulation of aging: results and prospects - Biogerontology 2009, Anisimov and Khavinson: overview of the Khavinson bioregulator class with documented modulation of endocrine function in aging models.
- Peptide Regulation of Aging: 35-Year Research Experience - Bulletin of Experimental Biology and Medicine 2009, Khavinson and Anisimov: long-term review on tissue-specific tetrapeptides including pancreas-related uses in aging.
- Peptide bioregulators: A new class of geroprotectors, report 2. The results of clinical trials - Advances in Gerontology 2014, Khavinson, Kuznik and Ryzhak: clinical findings on pancreatic and endocrine Khavinson peptides in elderly populations.
